Ryoko Suzuki 1, Xiong Wei 1, Pamela K. Allen 1, James W. Welsh 1, James D. Cox 1, Ritsuko Komaki 1 and Steven H. Lin 1,2*
|
|
- Kristin McLaughlin
- 5 years ago
- Views:
Transcription
1 Suzuki et al. Radiation Oncology (2018) 13:258 RESEARCH Open Access Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis Ryoko Suzuki 1, Xiong Wei 1, Pamela K. Allen 1, James W. Welsh 1, James D. Cox 1, Ritsuko Komaki 1 and Steven H. Lin 1,2* Abstract Background: Small cell lung cancer (SCLC) can recur in the brain after whole-brain irradiation (WBI). We documented outcomes after treatment of such recurrences and sought predictors of local control and overall survival (OS). Materials and methods: Eighty-five patients with SCLC and brain recurrence after prophylactic or therapeutic WBI in were identified and data were extracted from the medical records. Survival was estimated with the Kaplan-Meier method, and univariate and multivariate Cox proportional hazards modeling was used to identify factors associated with OS or further brain progression. Results: Brain recurrence was treated by stereotactic radiosurgery (SRS) in 33 patients (39%), repeat WBI in 14 (16%), chemotherapy-only in 16 (19%), and observation in 22 (26%). Median OS time after brain recurrence (OSrec) was 4.3 months for all patients; 6-month OSrec rates were 58% after SRS, 21% after repeat WBI, 50% after chemotherapy-only, and 5% after observation (P < 0.001). Inferior OSrec was associated with poor performance status (ECOG score 3) and uncontrolled extracranial disease. Superior OSrec was associated with receipt of 4 chemotherapy cycles before brain recurrence and receipt of chemotherapy, SRS, or repeat WBI afterward. Receipt of chemotherapy after brain recurrence correlated with brain progression. Conclusions: Some patients with brain recurrence after WBI for SCLC can survive for extended periods with appropriate intervention, especially those with adequate performance status or controlled extracranial disease. Keywords: CNS control, WBRT, Stereotactic radiosurgery, Survival Background Whole-brain irradiation (WBI) is an important component of treatment for small cell lung cancer (SCLC), whether given prophylactically or to treat known brain metastases. Because SCLC has a high propensity to seed in the brain, disease recurrence in the brain after WBI is not uncommon despite the radiosensitivity of the disease [1, 2]. Treatment strategies for brain recurrence after initial therapy for SCLC are limited but include surgical * Correspondence: SHLin@mdanderson.org 1 Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX , USA 2 Present address: Department of Radiation Oncology, Tokyo Medical and Dental University, 1 Chome-5-45 Yushima, Bunkyō, Tokyo , Japan resection, stereotactic radiosurgery (SRS), repeat WBI, and chemotherapy. In one autopsy series, 65% of patients had evidence of brain metastases at autopsy, with the probability of brain metastases increasing with survival time to 80% after 2 years [3]. Extended survival times from the use of modern radiotherapy techniques [4, 5] and the enhanced ability to detect small asymptomatic brain metastases [6] collectively increase the likelihood that more patients will manifest brain recurrence after initial WBI therapy for SCLC [6]. Repeat WBI for brain metastases from a variety of tumor types including lung cancer has been shown to be effective for symptom palliation [7 11]. A benefit from The Author(s) Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Suzuki et al. Radiation Oncology (2018) 13:258 Page 2 of 10 re-irradiating brain recurrences has also been found for patients with SCLC, although the median survival time after re-irradiation remains relatively short at 2 to 6 months [2, 12, 13]. In one study, patients with SCLC who developed brain metastases after prophylactic cranial irradiation (PCI) had effective symptom palliation from either repeat WBI or SRS [12]. Another series of patients with SCLC and brain relapse after WBI confirmed the feasibility of SRS as a salvage option [13, 14]. Nevertheless, information on how best to treat SCLC that has recurred in the brain after WBI is still sparse. Considering the high prevalence and depressing prognosis associated with brain recurrence, identifying reliable prognostic factors would be helpful for choosing among the various available treatment strategies. In this single-institution retrospective study, we evaluated patients with SCLC who developed brain recurrence after WBI, with the goals of assessing outcomes and identifying prognostic factors that could influence survival and brain control. Methods After approval of this study by the appropriate institutional review board, we identified 85 patients with SCLC and brain recurrence after WBI, given either with therapeutic or prophylactic intent, from 1998 through 2015 at a single tertiary cancer center. Management strategies for those brain recurrences (SRS, repeat WBI, chemotherapy, or observation) were extracted from the patients medical records, as was the following demographic and clinical information: factors at the initial diagnosis [sex, race, initial disease stage (limited vs. extensive), the presence and number of brain metastases at initial diagnosis ( 4 vs. > 4), intent of the first WBI (prophylactic vs. therapeutic), number of chemotherapy cycles before brain recurrences (< 4 vs. 4), and use and dose of thoracic radiation therapy (< 45 Gy vs. 45 Gy)]; factors at the brain recurrence [age, ECOG performance status (PS), symptoms and number of brain lesions ( 4 vs. > 4), the presence and status of extracranial disease (controlled vs. uncontrolled), and time from the initial WBI to the brain recurrence (< 6 months vs. 6 months)]; and factors after brain recurrence [treatment strategy (SRS, repeat WBI, chemotherapy only, or observation)]. Patients were typically given steroids, especially if they had symptoms, immediately upon diagnosis of brain recurrence. Patients with brain recurrence managed with observation were followed with best supportive care, including drugs such as steroids for symptom control. The primary endpoint of this study was overall survival after brain recurrence (OSrec), which was defined as the time from the date of brain recurrence to the date of death. Local control in the brain after brain recurrence (BCrec), evaluated radiologically or clinically, was defined as the time from the date of brain recurrence to the date of detection of further brain recurrence. Patients lost to follow-up were censored at the date of the last follow-up. Progression was defined as lesions that persisted after SRS, repeat WBI, or chemotherapy or, in the observation group, as brain recurrence. The Kaplan-Meier method was used to assess survival and progression probabilities, and log-rank tests were used to compare Kaplan-Meier estimates of event rates between potential predictors. Univariate and multivariate Cox proportional hazards models were used to assess associations between factors and survival or further disease progression in the brain, and those factors with a P value < 0.1 were used to construct the final multivariate Cox model. All analyses were two-sided, and significance was set at P <0.05. Statistical analyses were done with SPSS version 24 (SPSS, Chicago, IL, USA). Results Patient characteristics, stratified by treatment for brain recurrence, are summarized in Table 1. Among all 85 patients with brain recurrence after WBI, 10 (12%) had poor PS (i.e., ECOG 3 4); 24 (28%) had had limited SCLC; and 33 (39%) had received WBI for prophylaxis, with the other 52 (61%) receiving WBI with therapeutic intent. All 85 patients had extracranial disease at brain recurrence, which was controlled in 29 (34%). The median interval between the first WBI and the brain recurrence was 6.0 months (range, months). Brain recurrence was managed with SRS in 33 patients (39%), with repeat WBI in 14 (16%), with chemotherapy only in 16 (19%), and with observation (and best supportive care) in the remaining 22 patients (26%). Two of the patients in the SRS group had received SRS after craniotomy owing to the size of the lesion. One patient in the repeat WBI group had local fractionated radiotherapy rather than WBI. Of the 33 patients in the SRS group, 27 (82%) had 4 brain lesions at recurrence; by contrast, 9 patients (64%) in the repeat WBI group and 13 patients (59%) in the observation group had > 4 lesions. More than a third of patients in the SRS group also received additional chemotherapy, but only one patient in the repeat WBI group and no one in the observation group received further chemotherapy. Nineteen patients in the SRS group (58%) had further brain failure, and 5 of those patients received a second SRS; 2 patients who received a second SRS had a third recurrence, which was treated with salvage WBI; and 1 was treated with salvage WBI. Thirteen patients in the chemotherapy-only group (81%) had further brain failure; 1 was treated with SRS, 1 was treated with SRS and had a second recurrence also treated with SRS, 2 were treated with SRS and had a second recurrence treated with salvage WBI, and 3 were treated with salvage WBI.
3 Suzuki et al. Radiation Oncology (2018) 13:258 Page 3 of 10 Table 1 Patient characteristics by treatment received for brain recurrence All Patients (n = 85) Age at brain recurrence, years Group 1 (SRS) Group 2 (WBI) Group 3 (Chemo only) (n = 33) a (n = 14) b (n = 16) < ECOG performance status score at brain recurrence Sex Male Female Ethnicity White Non-white Initial disease stage Limited Extensive Brain metastases at initial diagnosis No Yes No. of brain lesions at initial diagnosis > Intent of first brain irradiation Prophylactic Therapeutic chemo cycles before brain recurrence No Yes Thoracic radiation therapy dose, Gy < No. of brain lesions at brain recurrence > Symptoms from brain lesions at brain recurrence No Yes Extracranial disease at brain recurrence Controlled Uncontrolled Chemotherapy after brain recurrence No Yes Group 4 (Observation) (n = 22)
4 Suzuki et al. Radiation Oncology (2018) 13:258 Page 4 of 10 Table 1 Patient characteristics by treatment received for brain recurrence (Continued) All Patients (n = 85) Time from the end of first brain irradiation to brain recurrence, mo Group 1 (SRS) Group 2 (WBI) Group 3 (Chemo only) (n = 33) a (n = 14) b (n = 16) < a Two patients received SRS with a Gamma knife after craniotomy b One patient received local (not whole-brain) radiation to tumor site using conventional radiotherapy Abbreviations: SRS stereotactic radiosurgery, WBI whole-brain irradiation, ECOG Eastern Cooperative Oncology Group Group 4 (Observation) (n = 22) Ten patients in the repeat-wbi group (71%) had further brain failure, of whom 1 had a craniotomy and the other 9 received best supportive care. The median total dose of the first course of WBI was 30 Gy (range, Gy), given in a median 3 Gy per fraction (range, 2 3 Gy). Most patients given repeat WBI received 20 Gy in ten 2-Gy fractions. For patients who received SRS, the prescribed dose was Gy per lesion depending on their size and location. The median OSrec time (i.e., survival after brain recurrence) was 4.3 months (95% confidence interval [CI] ) for the whole group. Median OSrec time for those with ECOG PS 0 2 at recurrence was 5.0 months (95% CI ) compared with 1.2 months (95% CI ) for those with PS 3 (P < 0.001) (Fig. 1a). Median OSrec time for those with extracranial disease control at brain recurrence was 9.1 months (95% CI ) compared with 3.2 months (95% CI ) for those with uncontrolled extracranial disease (P < 0.001) (Fig. 1b). Rates of OSrec at 6 months were different according to type of treatment for the recurrence: 58% for the SRS group, 21% for the repeat WBI group, 50% for the chemotherapy-only group, and 5% for the observation group (P < 0.001) (Fig. 1c). Further brain progression during follow-up was noted in 59 of the 85 patients. The median BCrec interval (i.e., brain control after brain recurrence) was 3.6 months (95% CI ) for the entire group. As for factors influencing OSrec, univariate analysis showed that worse OSrec was associated with poor PS ( 3) at recurrence, the presence of symptomatic brain lesions, and the presence of uncontrolled extracranial disease; better OSrec was associated with receipt of 4 chemotherapy cycles before brain recurrence, receipt of chemotherapy after brain recurrence, receipt of repeat WBI or SRS for brain recurrence, and an interval of 6months from the end of the first WBI to the brain recurrence. Univariate analysis for factors associated with BCrec showed that worse BCrec was associated with poor PS ( 3), > 4 brain lesions at recurrence, symptomatic brain lesions, and uncontrolled extracranial disease; better BCrec was associated with receipt of repeat WBI or SRS for the brain recurrence. OSrec and BCrec did not differ for patients with limitedversus extensive-stage disease at initial diagnosis (Table 2). In multivariate analysis, worse OSrec was associated with poor PS ( 3) at brain recurrence (hazard ratio [HR] 3.039, 95% CI , P = 0.006) and uncontrolled extracranial disease (HR 3.059, 95% CI , P < 0.001). Improved OSrec was associated with receipt of 4 chemotherapy cycles before brain recurrence (HR 0.351, 95% CI , P = 0.045); receipt of chemotherapy for brain recurrence (HR 0.174, 95% CI , P < 0.001); and receipt of repeat brain irradiation (with WBI or Gamma-knife) for brain recurrence (HR 0.367; 95% CI ; P < 0.001). As for BCrec, receipt of chemotherapy after brain recurrence was borderline significant in univariate analysis for BCrec (P = 0.085) but became significant in multivariate analysis after adjustment for other variables that were significant at P < 0.1 in univariate analysis (HR 0.457, 95% CI , P = 0.01), indicating that receipt of chemotherapy after brain recurrence may be associated with better BCrec. Uncontrolled extracranial disease and receipt of repeat brain irradiation (with WBI or Gamma-knife) for brain recurrence were marginally significant in multivariate analysis of BCrec (P = and P = 0.050). No other factors were found to be associated with BCrec in multivariate analysis (Table 3). Ten of the 85 patients in our study lived for more than 1 year after the first brain recurrence (Table 4). Notably, 8 of those 10 patients did not have liver or bone involvement at initial diagnosis. Moreover, Patients 5 and 7, who received temozolomide (without re-irradiation) for the initial recurrence later underwent SRS for a subsequent brain recurrence. Therefore all 10 of these patients had received SRS, whether for the initial or subsequent brain recurrence. Discussion Available options for patients with disease recurrence in the brain after WBI for SCLC are limited, but our findings suggest that some patients can expect better survival when those recurrences are treated with therapeutic intent by using SRS, repeat WBI, or chemotherapy, especially patients with adequate PS or controlled extracranial disease. Despite the radiosensitivity of SCLC, brain recurrence after WBI is not uncommon [1, 2]. In one meta-analysis
5 Suzuki et al. Radiation Oncology (2018) 13:258 Page 5 of 10 Fig. 1 Kaplan-Meier plot of survival after brain failure after wholebrain irradiation for small cell lung cancer by (a) Eastern Cooperative Oncology Group performance status score (ECOG PS); (b) extracranial disease control; or (c) form of treatment for brain recurrence. Survival after brain failure was significantly better for patients with superior PS, extracranial disease control, and intervention than for those with poor PS, uncontrolled extracranial disease, and observation/best supportive care. SRS, stereotactic radiosurgery; WBI, whole-brain irradiation A B C of 7 trials comparing PCI with no PCI for patients with limited-stage SCLC, 27% of all patients had disease recurrence in the brain [1]. Another retrospective series revealed brain recurrence in 15% of patients with SCLC after WBI; all of those recurrences were treated with either repeat WBI (12%) or SRS (3%) [2]. In the current study, we found that both PS and extracranial disease control were important contributors to survival after brain recurrence. Although these results were not entirely consistent with those of other studies (perhaps because of patient heterogeneity), some other studies also found these factors to be important for survival in such cases. Among several studies of prognostic factors and outcomes after re-irradiation with WBI for various malignancies including lung cancer [7 11], one showed that repeat WBI relieved symptoms in 71% of treated patients, and even though the median survival time after re-irradiation was short at 4 months, the 1-year survival rate for patients with no extracranial metastases was better at 14% versus only 4% for those with extracranial metastases [7]. A similar study also found better prognosis among patients with stable extracranial disease at re-irradiation [8]. In addition to extracranial disease control, high Karnofsky performance score (KPS) [9 11], the absence of severe symptoms [10], and longer interval between the two courses of WBI [11] have also been correlated with improved survival in other studies. A few studies have also examined the feasibility of SRS for brain metastases after WBI for various cancers, including lung [15 17]. In one such study, salvage SRS produced a median survival time of 8.4 months overall, and was longer for patients with a single brain metastasis than for those with multiple brain metastases (12.0 vs. 7.9 months) [15]. Another study found that high KPS, controlled extracranial metastases, and a good response to re-irradiation all had positive effects on survival [16]. The importance of KPS was also confirmed in another study, along with neurologic function [17]. Although available data are limited, we did find a few studies that addressed treatment for brain recurrences after WBI in SCLC. One study reported a benefit from brain retreatment with WBI or SRS among patients with SCLC and post-pci brain metastases; in that study, 40% of symptomatic patients achieved symptom palliation
6 Suzuki et al. Radiation Oncology (2018) 13:258 Page 6 of 10 Table 2 Univariate analysis of factors affecting survival and further brain control after recurrence in the brain after therapeutic or prophylactic irradiation Characteristics Survival after Brain Failure Brain Control after Brain Failure Age at brain recurrence, years Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value < ( ) ( ) ECOG performance status score at brain recurrence Sex < ( ) ( ) Male Female ( ) ( ) Ethnicity White Non-white ( ) ( ) Initial disease stage Limited Extensive ( ) ( ) Brain metastases at initial diagnosis No Yes ( ) 1.19 ( ) No. of brain lesions at initial diagnosis > ( ) ( ) Intent of first brain irradiation Prophylactic Therapeutic ( ) ( ) 4 chemo cycles before brain recurrence No Yes ( ) ( ) Thoracic radiation therapy dose, Gy < ( ) ( ) No. of brain lesions at brain recurrence > ( ) ( ) Symptoms from brain metastases at brain recurrence No Yes ( ) ( ) Extracranial disease at brain recurrence Controlled 1.00 < Uncontrolled ( ) ( ) Chemotherapy after brain recurrence No 1.00 < Yes ( ) 0.62 ( )
7 Suzuki et al. Radiation Oncology (2018) 13:258 Page 7 of 10 Table 2 Univariate analysis of factors affecting survival and further brain control after recurrence in the brain after therapeutic or prophylactic irradiation (Continued) Characteristics Survival after Brain Failure Brain Control after Brain Failure Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value WBI or G-knife for brain recurrence No Yes ( ) ( ) Time from the end of first brain irradiation to brain recurrence, mo < ( ) 0.77 ( ) Abbreviations: ECOG Eastern Cooperative Oncology Group, WBI whole-brain irradiation, G-knife Gamma knife therapy after re-irradiation, and the median survival times were 3 months after repeat-wbi and 5 months after SRS. That study further showed that patients with higher KPS ( 50) had significantly improved survival after re-irradiation, a finding that is comparable to ours [12]. The importance of PS in survival was also confirmed in a study that used salvage SRS after WBI; other factors found to be significant were tumor volume and the interval between SCLC diagnosis and the appearance of brain metastases [14]. Another retrospective study assessing the efficacy of salvage SRS after WBI for SCLC showed that although the median OS time for all patients was 5.9 months, 24% of patients survived for at least 12 months, and patients with no evidence of extracranial disease had Table 3 Multivariate analysis of factors affecting survival and further brain control after recurrence in the brain after therapeutic or prophylactic irradiation Characteristics Survival after Brain Failure Brain Control after Brain Failure Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value ECOG performance status score at brain recurrence ( ) ( ) 4 chemo cycles before brain recurrence No Yes ( ) No. of brain lesions at brain recurrence > ( ) ( ) Symptom from brain metastases at brain recurrence No Yes ( ) ( ) Extracranial disease at brain recurrence Controlled 1.00 < Uncontrolled ( ) ( ) Chemotherapy after brain recurrence No 1.00 < Yes ( ) ( ) WBI or G-knife for brain recurrence No Yes ( ) ( ) Time from first brain irradiation to brain recurrence, mo < ( ) Abbreviations: ECOG Eastern Cooperative Oncology Group, WBI whole-brain irradiation, G-knife Gamma knife therapy
8 Suzuki et al. Radiation Oncology (2018) 13:258 Page 8 of 10 Table 4 Characteristics of the ten patients who lived more than 1 year after brain recurrence Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 OSrec, mo Age at brain recurrence, years ECOG PS score at brain recurrence Sex Male Female Female Female Female Female Female Male Male Female Initial disease stage (limited or extensive) Extensive Extensive Extensive Extensive Extensive Extensive Extensive Extensive Limited Limited Extrathoracic organs involved at initial diagnosis No. of brain lesions at brain recurrence (1, 2 4 or 5) Symptoms from brain lesions at brain recurrence (no or yes) Extracranial disease at brain recurrence Time from the end of first brain irradiation to brain recurrence, mo. Treatment received for brain lesion after brain recurrence Chemotherapy after brain recurrence (no or yes) Additional brain failure after initial brain recurrence after WBI (no or yes) Salvage therapy for additional brain failure after initial brain recurrence after WBI Brain, adrenal Bone Liver Thyroid Brain Brain Brain None a None None No No No No No No No No No Yes Controlled Uncontrolled Controlled Controlled Controlled Controlled Controlled Controlled Controlled Uncontrolled SRS (after surgery) SRS SRS SRS SRS Temozolomide Temozolomide SRS SRS SRS Yes Yes Yes No Yes No Yes No No Yes Yes No Yes Yes Yes Yes Yes Yes Yes No Chemo Chemo SRS, repeat WBI afterwards SRS SRS SRS Observation Observation a Separate tumor nodule in contralateral lobe Abbreviations: OSrec overall survival time after brain recurrence, ECOG PS Eastern Cooperative Oncology Group performance status, SRS stereotactic radiosurgery, WBI whole-brain irradiation significantly better survival than did patients with stable or progressive extracranial disease [13]. Our findings also showed that patients who received 4 cycles of chemotherapy before brain recurrence had better survival, perhaps because of a lower systemic disease burden. We also found that patients who received chemotherapy after brain recurrence had better survival and better brain control than those who did not. Although several new chemotherapy agents have been evaluated in phase II trials for second-line treatment of SCLC, to date they have not resulted in changes to standard practice, which is currently platinum plus etoposide for first-line therapy and topotecan for second-line therapy [18]. Further improvements in systemic therapy, such as targeted agents and immune checkpoint inhibitors, are eagerly awaited.
9 Suzuki et al. Radiation Oncology (2018) 13:258 Page 9 of 10 We found that all 10 of the patients who lived for more than 1 year after brain recurrence received SRS, whether for initial or subsequent brain recurrence, a finding that highlights the importance of local treatment to improve outcome [19, 20]. The graded prognostic assessment (GPA) is advocated as a reliable and useful tool for estimating survival and for selecting appropriate treatment strategies for patients with brain metastases [21]. The original GPA score included age, KPS, number of brain lesions, and the presence or absence of extracranial metastases and has been validated for its prognostic potential in lung cancer [22, 23]. Although we also identified PS and extracranial disease control as significant prognostic factors, we could not calculate GPA in our patient population because they not only had recurrent disease but they also tended to have a more extensive systemic disease burden than the patients included in the development of the GPA analysis. This study had some limitations that should be considered in interpreting our results, chief among them being its retrospective nature, broad patient heterogeneity, and relatively small sample size. We cannot rule out the possibility that our findings could reflect selection bias. Thus our results should be considered exploratory and ideally should be validated in a larger, prospective cooperative group study. Conclusions The prognosis for patients with SCLC that recurs in the brain after WBI is still rather dismal, but survival in some cases, particularly those with adequate PS and controlled extracranial disease, can be extended if the recurrence is managed therapeutically. Abbreviations BCrec: Brain control after brain recurrence; ECOG: Eastern Cooperative Oncology Group; GPA: Graded prognostic assessment; KPS: Karnofsky performance score; OS: Overall survival; OSrec: Overall survival after brain recurrence; PCI: Prophylactic cranial irradiation; PS: Performance status; SCLC: Small cell lung cancer; SRS: Stereotactic radiosurgery; WBI: Whole-brain irradiation Acknowledgments We appreciate the editorial contributions of Christine F. Wogan, MS, ELS, of MD Anderson s Division of Radiation Oncology, in the development and revision of this report. Funding This work was supported in part by the National Cancer Institute, National Institutes of Health [Cancer Center Support (Core) Grant P30 CA to The University of Texas MD Anderson Cancer Center]. Availability of data and materials Please contact author for data requests. Authors contributions RS conceived the study, participated in its design and planning, oversaw the data collection and statistical analyses, and wrote the manuscript. XW and PKA extracted patient information from a departmental database, interpreted those data with regard to the nature and timing of the interventions and recurrence patterns, and conducted statistical analyses. JWW, JDC, RK, and SHL participated in the study design, provided patients for the analysis, oversaw their clinical care, and helped with the interpretation of the results. All authors read and approved the final manuscript. Ethics approval and consent to participate This retrospective study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. Consent for publication Not applicable. Competing interests Dr. Welsh receives funding from The Family of M. Adnan Hamed; The Susan and Peter Goodwin Foundation; Mabuchi Research fund; the Weigand Foundation; and The Orr Family Foundation (to MD Anderson Cancer Center s Thoracic Radiation Oncology program). Dr. Lin has grants from Genentech, Hitachi Chemical Diagnostics, New River Labs, Peregrine, BeyondSpring Pharmaceuticals, and STCube Pharmaceuticals and is on the advisory board for AstraZeneca. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Received: 10 April 2018 Accepted: 18 December 2018 References 1. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med. 1999;341(7): Bernhardt D, Adeberg S, Bozorgmehr F, et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neuro-Oncol. 2017;134(1): Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979;44(5): Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT study team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limitedstage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8): Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4): Kushnirsky M, Nguyen V, Katz JS, et al. Time-delayed contrast-enhanced MRI improves detection of brain metastases and apparent treatment volumes. J Neurosurg. 2016;124(2): Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys. 1996;34(3): Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA. Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(2):e Scharp M, Hauswald H, Bischof M, Debus J, Combs SE. Re-irradiation in the treatment of patients with cerebral metastases of solid tumors: retrospective analysis. Radiat Oncol. 2014;3(9): Aktan M, Koc M, Kanyilmaz G, Tezcan Y. Outcomes of reirradiation in the treatment of patients with multiple brain metastases of solid tumors: a retrospective analysis. Ann Transl Med. 2015;3(21): Ozgen Z, Atasoy BM, Kefeli AU, Seker A, Dane F, Abacioglu U. The benefit of whole brain reirradiation in patients with multiple brain metastases. Radiat Oncol. 2013;8: Bernhardt D, Bozorgmehr F, Adeberg S, et al. Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. Lung Cancer. 2016;101: Harris S, Chan MD, Lovato JF, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):e53 9.
10 Suzuki et al. Radiation Oncology (2018) 13:258 Page 10 of Sheehan J, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg. 2005;102(Suppl): Caballero JA, Sneed PK, Lamborn KR, et al. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1): Huang Z, Sun B, Shen G, et al. Brain metastasis reirradiation in patients with advanced breast cancer. J Radiat Res. 2017;58(1): Maranzano E, Trippa F, Casale M, et al. Reirradiation of brain metastases with radiosurgery. Radiother Oncol. 2012;102(2): Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180: Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after firstline systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12): Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2): Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3): Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):
Outcomes after Reirradiation for Brain Metastases
Original Article PROGRESS in MEDICAL PHYSICS Vol. 26, No. 3, September, 2015 http://dx.doi.org/10.14316/pmp.2015.26.3.137 Outcomes after Reirradiation for Brain Metastases Jesang Yu, Ji Hoon Choi, Sun
More informationAdditional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer
Sun et al. Radiation Oncology (2018) 13:250 https://doi.org/10.1186/s13014-018-1198-4 RESEARCH Open Access Additional radiation boost to whole brain radiation therapy may improve the survival of patients
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationPrognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for Recurrent Brain Metastases After Prior Whole Brain Radiotherapy
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Metastases Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationNonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis
1998 Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis Chaosu Hu, M.D. 1 Eric L. Chang, M.D. 2 Samuel J. Hassenbusch III, M.D., Ph.D. 3 Pamela K. Allen, Ph.D. 2 Shiao Y. Woo,
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationStandard care plan for Prophylactic Cranial Irradiation for Limited Stage (stage I-III) Small Cell Lung Cancer (25Gy in 10 fractions) References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Prophylactic Cranial Irradiation for Limited-stage Small Cell Lung Cancer (20Gy in 5 fractions) Clinical Guideline Standard Care
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationBrain metastases are common brain malignant neoplasms
J Neurosurg (Suppl) 117:49 56, 2012 Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non small cell lung cancer
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationEvidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY
GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationProphylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?
Editorial Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again? Cecile Le Pechoux 1, Angela Botticella 1, Antonin
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationProphylactic cranial irradiation for extensive-stage small-cell lung cancer: an evolving view
Editorial Prophylactic cranial irradiation for extensive-stage small-cell lung cancer: an evolving view Ethan B. Ludmir, Steven H. Lin Department of Radiation Oncology, The University of Texas MD Anderson
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More information1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL
Current treatment practices for limited-stage small cell lung cancer: A survey of US radiation oncologists on the timing of thoracic radiotherapy with chemotherapy Matthew J. Farrell 1, Jehan Yahya 1,
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationResearch Article Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?
Oncology Volume 2008, Article ID 417137, 5 pages doi:10.1155/2008/417137 Research Article Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain? Carsten
More informationIntroduction: Methods: Results: Conclusions: PATIENTS AND METHODS Key Words: 1770
Original Article Utilization of Hyperfractionated Radiation in Small-Cell Lung Cancer and Its Impact on Survival David Schreiber, MD,* Andrew T. Wong, MD,* David Schwartz, MD,* and Justin Rineer, MD Introduction:
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,
More informationVINCENT KHOO. 8 th EIKCS Symposium: May 2013
8 th EIKCS Symposium: May 2013 VINCENT KHOO Royal Marsden NHS Foundation Trust & Institute of Cancer Research St George s Hospital & University of London Austin Health & University of Melbourne Disclosures
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationLiang-Hua Ma, Guang Li *, Hong-Wei Zhang, Zhi-Yu Wang, Jun Dang, Shuo Zhang and Lei Yao
Ma et al. Radiation Oncology (2016) 11:92 DOI 10.1186/s13014-016-0667-x RESEARCH Open Access The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationMetastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti
Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Brain Metastases Radiation Therapy of multiple brain metastases Is treatment appropriate? - Survival - QoL Brain Metastases
More informationClinical Study Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?
ISRN Oncology Volume 2013, Article ID 214304, 4 pages http://dx.doi.org/10.1155/2013/214304 Clinical Study Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain
More informationCécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced
More informationManagement of single brain metastasis: a practice guideline
PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease
More informationBrain metastases are detected in approximately 20%
COUNTERPOINTS Current Controversies in Hematology and Oncology Should All Patients With SCLC Receive Prophylactic Cranial Irradiation If They Have Responded to Treatment? Brain metastases are common in
More informationThe Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
Curr. Treat. Options in Oncol. (2015) 16: 56 DOI 10.1007/s11864-015-0372-2 Lung Cancer (HA Wakelee, Section Editor) The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer Kaname Nosaki, M.D.
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx332 Published online 27 June 2017
Annals of Oncology 28: 2588 2594, 217 doi:1.193/annonc/mdx332 Published online 27 June 217 ORIGINAL ARTICLE Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients
More informationAccepted Manuscript. Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer. Jessica S. Donington, MD, MSCR
Accepted Manuscript Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer Jessica S. Donington, MD, MSCR PII: S0022-5223(18)32903-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.10.124 Reference:
More informationPrognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
Kaul et al. Radiation Oncology (2015) 10:244 DOI 10.1186/s13014-015-0550-1 RESEARCH Open Access Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer David Kaul
More informationMehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey
Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest,
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationNeurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex
ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):111-115 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.111 Neurological Change after Gamma Knife Radiosurgery for Brain Metastases
More informationOriginal Study. 40 Clinical Lung Cancer January 2013
Original Study Prophylactic Cranial Irradiation for Patients With Limited-Stage Small-Cell Lung Cancer With Response to Chemoradiation Patricia Tai, 1 Avi Assouline, 2 Kurian Joseph, 3 Larry Stitt, 4 Edward
More informationDisclosure for Dr. Gomez
Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized,
More informationRESEARCH HUMAN CLINICAL STUDIES
TOPIC RESEARCH HUMAN CLINICAL STUDIES RESEARCH HUMAN CLINICAL STUDIES Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis Jared R. Robbins, MD* Samuel Ryu, MD* Steven
More informationPlace de la radiothérapie dans les CBPC métastatiques
Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early
More informationPalliative radiotherapy in lung cancer
New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer
More informationDepartment of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway 2
The Scientific World Journal Volume 212, Article ID 69323, 5 pages doi:1.11/212/69323 The cientificworldjournal Clinical Study Towards Improved Prognostic Scores Predicting Survival in Patients with Brain
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk
More informationOutcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases
ORIGIL ARTICLE Brain Tumor Res Treat 2013;1:64-70 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationLocal control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin
J Neurosurg 104:907 912, 2006 Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin MICHAEL A. VOGELBAUM, M.D., PH.D., LILYANA ANGELOV, M.D., SHIH-YUAN
More informationARROCase Brain Metastases
ARROCase Brain Metastases Colin Hill*, Daniel M. Trifiletti*, Timothy N. Showalter*, Jason P. Sheehan Radiation Oncology* and Neurosurgery University of Virginia Charlottesville, VA Case: HPI 64 year old
More informationTreating Multiple. Brain Metastases (BM)
ESTRO 36 5-9 May 2017, Vienna Austria, Accuray Symposium Treating Multiple Brain Metastases (BM) with CyberKnife System Frederic Dhermain MD PhD, Radiation Oncologist Gustave Roussy University Hospital,
More informationStereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases
ONCOLOGY REPORTS 29: 407-412, 2013 Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases SHELLY LWU 1, PABLO GOETZ 1, ERIC MONSALVES 1, MANDANA ARYAEE 1, JULIUS
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationProlonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications
Japanese Journal of Clinical Oncology, 2015, 45(8) 713 718 doi: 10.1093/jjco/hyv067 Advance Access Publication Date: 15 May 2015 Original Article Original Article Prolonged survival after diagnosis of
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationA prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
British Journal of Cancer (4) 91, 829 833 All rights reserved 7 9/4 $3. www.bjcancer.com A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic
More informationThe Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2016.79.4.274 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2016;79:274-281 The Younger Patients Have More Better Prognosis in Limited Disease
More informationNews Briefing: Treatment Considerations for Focused Populations
News Briefing: Treatment Considerations for Focused Populations Moderator: Pranshu Mohindra, MD, University of Maryland, Baltimore Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy
More informationProtocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart.
Protocolos de consenso: MTS Cerebrales Resumen ASTRO Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. ASTRO 2013 Brain met SRS Abstracts 97. Comparative Effectiveness of SRS versus WBRT
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationTreatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation
Original Article Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation Masakuni Sakaguchi 1, Toshiya Maebayashi 1, Takuya Aizawa 1, Naoya Ishibashi 1, Tsutomu
More informationSTEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS
STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS Yousefi Kashi A. SH, Mofid B. 1 Department of Radiation Oncology,Shohada Tajrish Hospital,Shahid Beheshti University
More informationBr a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases.
J Neurosurg 111:825 831, 2009 The results of resection after stereotactic radiosurgery for brain metastases Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o l k a, M.D.,
More informationCNS Metastases in Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationMelanoma, a deadly and aggressive cancer, is the
See the corresponding editorial in this issue, pp 225 226. J Neurosurg 117:227 233, 2012 Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Clinical
More informationSUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT
SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1
More informationRESEARCH ARTICLE. Evrim Bayman 1 *, Durmus Etiz 1, Melek Akcay 1, Guntulu Ak 2. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.15.6263 RESEARCH ARTICLE Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution
More information8/2/2018. Acknowlegements: TCP SPINE. Disclosures
A Presentation for the AAPM Annual meeting, Aug 2, 2018 Nashville, TN Stereotactic Radiosurgery for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards for Future
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationPlace of tumor bed radiosurgery and focal radiotherapy following resec7on of brain metastases: A new paradigm Lucyna Kepka
Place of tumor bed radiosurgery and focal radiotherapy following resec7on of brain metastases: A new paradigm Lucyna Kepka Department of Radia7on Oncology; M. Sklodowska- Curie Memorial Cancer Center and
More informationSMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.
More informationABSTRACT Question 1 Target population Recommendations Question 2 Question 3 Keywords:
CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON THE ROLE OF CHEMOTHERAPY IN THE MANAGEMENT OF ADULTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS Sponsored by The Congress
More informationShoji Yomo 1,2* and Motohiro Hayashi 2
Yomo and Hayashi BMC Cancer (2015) 15:95 DOI 10.1186/s12885-015-1103-6 RESEARCH ARTICLE Open Access Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer?
More informationOriginal Article Value of Adding Boost to Whole Brain Radiotherapy after Surgical Resection of Limited Brain Metastases
Egyptian Journal of Neurosurgery Volume 29 / No. 4 / October - December 2014 39-44 Original Article Value of Adding Boost to Whole Brain Radiotherapy after Surgical Resection of Limited Brain Metastases
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationSurgery for recurrent brain metastases
Surgery for recurrent brain metastases Pr Philippe METELLUS Neurosurgeon, Clairval Hospital Center, Marseille 8th Annual Brain Metastases Research and Emerging Therapy Conference September 21st, 2018 Conflict
More informationJAMA. 2006;295:
ORIGINAL CONTRIBUTION Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases A Randomized Controlled Trial Hidefumi Aoyama, MD,
More informationLocal control after fractionated stereotactic radiation therapy for brain metastases
J Neurooncol (2014) 120:339 346 DOI 10.1007/s11060-014-1556-5 CLINICAL STUDY Local control after fractionated stereotactic radiation therapy for brain metastases Selvan Rajakesari Nils D. Arvold Rachel
More informationRadiotherapy for Brain Metastases
Radiotherapy for Brain Metastases Robert B. Den, MD a, David W. Andrews, MD b, * KEYWORDS Brain metastases Treatment approaches SRS WBRT The optimal treatment of brain metastases remains controversial.
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationClinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases
Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic
More informationTreatment of Recurrent Brain Metastases
Treatment of Recurrent Brain Metastases Penny K. Sneed, M.D. Dept. of Radiation Oncology University of California San Francisco Background Brain metastases occur in 8.5-15% of cancer pts in population-
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationBrain metastases arise in 10% 40% of patients
J Neurosurg (Suppl) 117:38 44, 2012 Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone Clinical article
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationConflicts of Interest
Dose Constraints to Prevent Radiation-Induced Brachial Plexopathy for Unresectable Lung Cancer Amini A*, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More information